Grants History

Angiosarcoma Awareness is proud to have awarded the following grants:


Vinod Ravi, MD, The University of Texas M.D. Anderson Cancer Center, Houston, TX. “Development of patient-derived Angiosarcoma cell line model to investigate synthetic lethality”. $12,000


Sarcoma Alliance. Patient advocacy and access to second opinions. $30,000

Nikhil Wagle, MD, Broad Institute of MIT and Harvard.  “Germline Analysis for Pathogenic Variants in Angiosarcoma” $100,000


Greg Cote, MD, Massachusetts General Hospital.$25,000


Jun-lin Guan, Ph.D., University of Cincinnati College of Medicine. “Therapeutic targeting of mTORC1 for lymphangiosarcoma using a novel mouse model”. $43,200


Greg Cote, MD, Massachusetts General Hospital. “Development of an angiosarcoma patient-derived xenograph mouse model”. $50,000


Brian Van Tine, MD, Ph.D., Washington University School of Medicine, St. Louis MO. “Establishing an integrative Omics Approach to Identify Therapeutic Targets in Angiosarcoma”. $27,000

Nancy Demore, MD, Medical University of South Carolina, “Generation of a Pegylated SFRP2 Fragmented Antibody for the treatment of Angiosarcoma”. $25,000


Vinod Ravi, MD, MD Anderson Cancer Center, Houston, Tx. “Identification of therapeutic targets in angiosarcoma using genomic and proteomic analysis and in vivo evaluation of the efficacy of inhibitors to identified tumor explants”. $25,000

Soner Altiok, MD, Ph.D., H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL. “Assessment of the Therapeutic Efficacy of Wee1 Inhibition in Patient Derived Xenograph Mouse Models of Human Angiosarcoma”. $25,000

Through a partnership with Cycle for Survival, the following grant was also funded in 2013:

Cristina Antonescu, MD, Memorial Sloan-Kettering. “Upregulation of angiogenic regulators in angiosarcoma using genomic approaches to investigate dysregulation in miRNAs and whole genome methylation”. $50,000


Jaime Modiano, VMD, Ph.D., Veterinary Medicine and Masonic Cancer Center University of Minnesota. “Innovative Molecular Targets for Prevention and Treatment of Canine Hemangiosarcoma”. $50,000